Chicago, USA. 2010.2.16 - Abbott today announced its' EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products.
 

 
"The acquisition of Solvay Pharmaceuticals is a key part of Abbott's strategy to bolster our presence in key markets and deliver sustainable, industry-leading growth," said Miles D. White, chairman and chief executive officer, Abbott. "In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth."
 
Solvay Pharmaceuticals is now part of Abbott's global Pharmaceutical Products Group.
 
Abbott has a strong portfolio of specialty pharmaceuticals, and Solvay brings successful, consistently performing products – including branded generics – that will further diversify Abbott's pharmaceutical business and provide significant growth opportunities. These products complement Abbott's presence and expertise in specialty markets such as cardiovascular disease, neuroscience and gastroenterology, and include treatments for men's and women's hormonal health, and exocrine pancreatic insufficiency (inability to properly digest food), which is associated with several underlying conditions including cystic fibrosis and chronic pancreatitis.
 
"The combination of Solvay and Abbott's pharmaceutical businesses will enable Abbott to attain leadership in key emerging markets, where there is significant opportunity for branded generics," said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott. "The addition of Solvay Pharmaceuticals is the catalyst for Abbott's growth and leadership in this area, and will ensure Abbott has the infrastructure, reach and product offerings to continue meeting the needs of patients around the world."
 
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its' products in more than 130 countries.
 
In Australia, Digital Tsunami has delivered online and offline marketing collaterals for Solvay. First was the localised website for Solvay Pharmaceuticals, then an online ordering system for Influvac, and interactive CD-ROMs for Creon.
 
Digital Tsunami was founded in Hong Kong in 1996 and Essential, (its' film production division, founded in 1980), has delivered solutions to multinational corporations and global brands including; Citizen, Coca-Cola, Mercedes-Benz, Merck and NEC.
 
If you have requirements for medical, pharmaceutical, commercial or corporate online or film projects, contact us to benefit from our expertise.